Back to Agenda
Session 5: Potential Tools for Clinical Documents and Data Anonymisation
Session Chair(s)
Julie Holtzople
Independent Consultant, Holtzople Consulting, United States
Industry has significant experience with use of redaction in delivery of Redacted Clinical Packages and the use of the qualitative risk assessment approach. To drive better clinical utility, we must find tools that support use of additional anonymisation techniques and the ability to measure the risk associated with a submission that can support scalable delivery of Redacted Clinical Packages. In this session we will seek examples of potential tools which have been developed by vendors to measure risk and/or anonymise beyond redaction. The sessions are designed to ask vendors to demonstrate how their tool goes beyond redaction and supports risk assessment in the anonymisation of clinical documents. The session is designed to allow participants a chance to see all potential tools and seek potential solutions for their companies. This session will focus on tools, not services.
Speaker(s)
Cathal Gallagher
Associate Director Clinical Transparency & Trial Disclosure, Regeneron, United Kingdom
De-Identification Vendor Showcase (Blur)
Stephen Morehouse, MBA, MS
Management Consultant, PA Consulting, United States
Automating the Redaction and Anonymisation of Unstructured Patient Data Using Deep Natural Language Processing Software (The ARARA platform)
Stephen Doogan
Chief Product Officer, Real Life Sciences, Inc., United States
Automating the Redaction and Anonymisation of Unstructured Patient Data Using Deep Natural Language Processing Software (The ARARA platform)
Jack Yeager
CEO, Sylogent, United States
Online Structured Authoring is the Key to Automated Document Redaction and Anonymising Data (SYQUENCE)
Woo Song
CEO, Xogene, United States
A Dual Technology Approach to Meeting Policy 0070 (Xogene Terminator)
Have an account?